VIGONVITA successfully listed on the main board of the Hong Kong Stock Exchange: Market value HKD 13.7 billion

Donews
2025.11.07 07:29

DoNews reported on November 7 that on November 6, Suzhou VIGONVITA-B Biotechnology Co., Ltd. (hereinafter referred to as VIGONVITA-B) successfully listed on the main board of the Hong Kong Stock Exchange. The opening stock price once surged over 190%, reaching a high of HKD 97 per share, and closed at HKD 82 per share on the same day, an increase of over 145%, with a total market value of approximately HKD 13.7 billion.

VIGONVITA-B's public offering period saw a subscription amount of HKD 279.7 billion, with an oversubscription of 4,974 times.

According to the prospectus, for the first four months of 2023 to 2025, its operating revenues were HKD 199.651 million, HKD 11.832 million, and HKD 12.958 million, respectively; net profits were HKD 6.427 million, -HKD 218 million, and -HKD 112 million. The company made a profit of HKD 6 million in 2023, incurred a loss of HKD 218 million in 2024, and reported a loss of HKD 112 million in the first four months of 2025

Source: Donews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.